The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant loss of -36.85% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -10.49%. Over the past 30 days, the price of BCRX has fallen by 3.57%. And in the last five days, it has surged by 5.99%.
The stock of BioCryst Pharmaceuticals Inc. (BCRX) is currently priced at $7.25. In the last session, the stock climbed significantly, topping out at $6.94 after opening at $6.94. The day’s lowest price was $6.72 before the stock closed at $6.85.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
BioCryst Pharmaceuticals Inc. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $14.50 on 10/14/22, while the lowest price for the same period was registered at $6.62 on 08/08/23.
52-week price history of BCRX Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. BioCryst Pharmaceuticals Inc.’s current trading price is -50.00% away from its 52-week high, while its distance from the 52-week low is 9.52%. The stock’s price range during this time has been between $6.62 and $14.50. The trading volume for the Healthcare sector company’s shares reached about 2.2 million for the day, which was lower than the average daily volume of 2.66 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
BioCryst Pharmaceuticals Inc. (BCRX) has experienced a quarterly decline of -2.16% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.39B and boasts a workforce of 531 employees.
BioCryst Pharmaceuticals Inc.: Analysts’ Ratings Unveiled
As of right now, 8 analysts are rating BioCryst Pharmaceuticals Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 7.55, with a change in price of -0.26. Similarly, BioCryst Pharmaceuticals Inc. recorded 2,588,933 in trading volume during the last 100 days, posting a change of -3.54%.
BCRX Stock Stochastic Average
Today’s raw stochastic average for BioCryst Pharmaceuticals Inc. over the last 50 days is 45.49%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 59.89%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 34.98% and 27.19%, respectively.
